Galapagos’ Rheumatoid Arthritis Drug Catches Investors Interest
Phase II study data on Galapagos’ rheumatoid arthritis drug has caused curiosity within the industry. Last week, the Belgian drug maker revealed statistics from a Phase II study of GLPG0634, which showed that the Janus kinase (JAK)-1 inhibitor reached the primary endpoint of significant improvement in the signs and symptoms of rheumatoid arthritis (RA). The 36-patient